XOMA Corporation (NASDAQ:XOMA)
XOMA Corporation (NASDAQ:XOMA), presented positive data from the pre-clinical studies which is evaluating the activity of the company’s anti-PTH1R antagonist monoclonal antibody (mAb). XOMA Corporation is engaged in the deveploment of antibody therapeutics. The product is a first class therapeutic agent used in humoral hypercalcemia of malignancy (HHM) and hyperparathyroidism (HPT) treatment. The company made the presentation at the Endocrine Society (ENDO) and American Association for Cancer Research (AACR) annual meetings.
The PTH1R receptor is one of the B GPCR family and is the main receptor of two ligands parathyroid related protein (PTHrP) and parathyroid hormone (PTH). Hypercalcemia manifest when raised PTH levels cause excessive PTH1R receptor activation. Long-acting or potent receptor rivals could overturn hypercalcemia when subjected to all these conditions
XOMA Corporation (NASDAQ:XOMA) Chief Executive Officer, Jim Neal, says they are seeking a partner who is highly experienced in drug development and interested licensing their first-in-class antibody. The partner will also be required to take the product through the process of clinical development. He added that there is an urgent need for treatment caused by hyperparathyroidism and hypercalcemia and the data presented is a morale booster as they show the efficacy of the company’s anti-PTH1R approach in treating HPT and HHM patients.
The company’s PTH1R program started as an endocrine program but due to its peculiar mechanism-of-action, the company saw a possible benefit to oncology patients with hypercalcemia, the company has also carried out the Vivo studies which have for PTH1R which has shown high levels of efficacy. This could be used to solve a big unmet medical demand. A number of mild and advanced HPT are highly challenging to control using pharmacological methods and can be solved using XOMA Corporation (NASDAQ:XOMA)’s anti-PTH1R antibody.
XOMA Corporation (NASDAQ:XOMA) has a large portfolio of programs, products and technologies that have been licensed to other pharmaceutical and biotech companies. Many of the licenses are from XOMA’s efforts in the discovery, development and marketing of antibody therapeutic products. XOMA Corporation (NASDAQ:XOMA) has over 20 similar programs that are financed by its partners and have the potential to produce royalty payments and milestone payments going forward. In an effort to optimize its licensing transaction value, the company has heavily invested in X358, which is an allosteric monoclonal antibody which is used to reduce on the activity of insulin receptor as the antibody has the potential to treat hyperinsulinism.
I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.
About the author: Monica Gray has an undergraduate degree in Accounting and an MBA – earned with Honors. She has six years of experience in the financial markets and has been a securities analyst for the past two years.